168 related articles for article (PubMed ID: 21606464)
1. CETP expression reverses the reconstituted HDL-induced increase in VLDL.
Wang Y; Berbée JF; Stroes ES; Smit JW; Havekes LM; Romijn JA; Rensen PC
J Lipid Res; 2011 Aug; 52(8):1533-41. PubMed ID: 21606464
[TBL] [Abstract][Full Text] [Related]
2. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
[TBL] [Abstract][Full Text] [Related]
3. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice.
de Vries-van der Weij J; Zadelaar S; Toet K; Havekes LM; Kooistra T; Rensen PC
Atherosclerosis; 2009 Sep; 206(1):153-8. PubMed ID: 19345354
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
[TBL] [Abstract][Full Text] [Related]
5. CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.
Bijland S; van den Berg SA; Voshol PJ; van den Hoek AM; Princen HM; Havekes LM; Rensen PC; Willems van Dijk K
J Lipid Res; 2010 Jan; 51(1):97-102. PubMed ID: 19564641
[TBL] [Abstract][Full Text] [Related]
6. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice.
Westerterp M; van der Hoogt CC; de Haan W; Offerman EH; Dallinga-Thie GM; Jukema JW; Havekes LM; Rensen PC
Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2552-9. PubMed ID: 16946130
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.
van der Hoogt CC; de Haan W; Westerterp M; Hoekstra M; Dallinga-Thie GM; Romijn JA; Princen HM; Jukema JW; Havekes LM; Rensen PC
J Lipid Res; 2007 Aug; 48(8):1763-71. PubMed ID: 17525476
[TBL] [Abstract][Full Text] [Related]
8. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.
Zhou E; Li Z; Nakashima H; Choukoud A; Kooijman S; Berbée JFP; Rensen PCN; Wang Y
Pharmacol Res; 2021 May; 167():105524. PubMed ID: 33667684
[TBL] [Abstract][Full Text] [Related]
10. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
[TBL] [Abstract][Full Text] [Related]
11. PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.
de Haan W; de Vries-van der Weij J; Mol IM; Hoekstra M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
Biochim Biophys Acta; 2009 Mar; 1791(3):191-7. PubMed ID: 19150509
[TBL] [Abstract][Full Text] [Related]
12. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
[TBL] [Abstract][Full Text] [Related]
13. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis.
Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR
Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395
[TBL] [Abstract][Full Text] [Related]
15. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
[TBL] [Abstract][Full Text] [Related]
16. Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice.
Pouwer MG; Pieterman EJ; Chang SC; Olsen GW; Caspers MPM; Verschuren L; Jukema JW; Princen HMG
Toxicol Sci; 2019 Apr; 168(2):519-534. PubMed ID: 30657992
[TBL] [Abstract][Full Text] [Related]
17. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.
Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
J Lipid Res; 2001 Feb; 42(2):241-8. PubMed ID: 11181754
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of cholesteryl ester transfer protein and defective apolipoprotein E in transgenic mice alters plasma cholesterol distribution. Implications for the pathogenesis of type III hyperlipoproteinemia.
Fazio S; Marotti KR; Lee YL; Castle CK; Melchior GW; Rall SC
J Biol Chem; 1994 Dec; 269(51):32368-72. PubMed ID: 7798236
[TBL] [Abstract][Full Text] [Related]
19. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
[TBL] [Abstract][Full Text] [Related]
20. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion.
Harada LM; Amigo L; Cazita PM; Salerno AG; Rigotti AA; Quintão EC; Oliveira HC
Atherosclerosis; 2007 Apr; 191(2):313-8. PubMed ID: 16806230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]